enGene Holdings Inc. Common Stock (ENGN NASDAQ) stock market data APIs
$3.7784
-0.02(-0.5%)
as of July 18, 2025
Try our APIs with
free plan!
enGene Holdings Inc. Common Stock Financial Data Overview
Price chart is built with
Anychart
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a non-viral monotherapy to treat non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) in patients that have been unresponsive to treatment with Bacillus Calmette-Guérin (BCG). enGene Holdings Inc. is based in Montreal, Canada.
Prev. Close
3.7784
Open
3.7552
High
3.7709
Low
3.6167
52 wk Range
2.7568-11
Market Cap
188 M
Shares Outstanding
51 105 K
EPS
-0.51
Beta
-0.391
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get enGene Holdings Inc. Common Stock data using free add-ons & libraries
Get enGene Holdings Inc. Common Stock Fundamental Data
enGene Holdings Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -87 810 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-06-12
- EPS/Forecast: -0.48
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
enGene Holdings Inc. Common Stock News
New
FDA grants RMAT designation to enGene's bladder cancer therapy
BOSTON/MONTREAL - The U.S. Food and Drug Administration has granted Regenerative Medicine Advanced Therapy (RMAT) designation to enGene Holdings Inc.’s (NASDAQ:ENGN) lead therapy for treating high-r...
Engene stock maintains buy rating at H.C. Wainwright on LEGEND trial
H.C. Wainwright has reiterated a buy rating and $25.00 price target on Engene Holdings Inc. (NASDAQ:ENGN), citing progress in the company’s pivotal LEGEND trial for high-risk non-muscle invasive bla...
Is enGene Holdings Inc. (ENGN) the Best Canadian Penny Stock to Invest in Now?
We recently published a list of 13 Best Canadian Penny Stocks to Invest in Now In this article, we are going to take a look at where enGene Holdings Inc. (NASDAQ:ENGN) stands against other best Canadi...
NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors
NewAmsterdam Pharma N.V. NAARDEN, The Netherlands and MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
